Trial Profile
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PANTHER
- 11 Jan 2024 The protocol has been amended to increase in study time fram for Median radiographic progression free survival (PFS) up to 4 years.
- 11 Jan 2024 Planned primary completion date changed from 31 Jan 2023 to 22 Feb 2025.
- 06 Jun 2023 Interim Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology